Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma

Acquired resistance to BRAF inhibitors often involves MAPK re‐activation, yet the MEK inhibitor trametinib showed minimal clinical activity in melanoma patients that had progressed on BRAF‐inhibitor therapy. Selective ERK inhibitors have been proposed as alternative salvage therapies. We show that E...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Oncol
Hlavní autoři: Carlino, Matteo S., Todd, Jason R., Gowrishankar, Kavitha, Mijatov, Branka, Pupo, Gulietta M., Fung, Carina, Snoyman, Stephanie, Hersey, Peter, Long, Georgina V., Kefford, Richard F., Rizos, Helen
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2014
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528644/
https://ncbi.nlm.nih.gov/pubmed/24476679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.01.003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky